BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23909849)

  • 1. Development of new treatment approaches for epilepsy: unmet needs and opportunities.
    French JA; White HS; Klitgaard H; Holmes GL; Privitera MD; Cole AJ; Quay E; Wiebe S; Schmidt D; Porter RJ; Arzimanoglou A; Trinka E; Perucca E
    Epilepsia; 2013 Aug; 54 Suppl 4():3-12. PubMed ID: 23909849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
    Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
    Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy development.
    O'Brien TJ; Ben-Menachem E; Bertram EH; Collins SD; Kokaia M; Lerche H; Klitgaard H; Staley KJ; Vaudano E; Walker MC; Simonato M
    Epilepsia; 2013 Aug; 54 Suppl 4():70-4. PubMed ID: 23909855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of drugs for the treatment of epilepsy.
    Mattson RH
    Semin Neurol; 1990 Dec; 10(4):406-13. PubMed ID: 2287835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pediatric epilepsy: European expert opinion, 2007.
    Wheless JW; Clarke DF; Arzimanoglou A; Carpenter D
    Epileptic Disord; 2007 Dec; 9(4):353-412. PubMed ID: 18077226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.
    Barker-Haliski M; Steve White H
    Neuropharmacology; 2020 May; 167():107750. PubMed ID: 31469995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs.
    Weaver DF
    Epilepsia; 2013 May; 54 Suppl 2():56-9. PubMed ID: 23646972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study.
    Gericke CA; Picard F; de Saint-Martin A; Strumia S; Marescaux C; Hirsch E
    Epileptic Disord; 1999 Sep; 1(3):159-65. PubMed ID: 10937148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review.
    Löscher W
    Methods Find Exp Clin Pharmacol; 1984 Sep; 6(9):531-47. PubMed ID: 6439966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma.
    Löscher W; Schmidt D
    Epilepsia; 2011 Apr; 52(4):657-78. PubMed ID: 21426333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy.
    Kim SH; Lee JH; Ryu HW; Lim BC; Chae JH; Choi JE; Hwang YS; Kim KJ
    Epileptic Disord; 2013 Mar; 15(1):49-54. PubMed ID: 23531645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies.
    Löscher W
    Epilepsy Res; 2016 Oct; 126():157-84. PubMed ID: 27505294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs.
    Hitiris N; Brodie MJ
    Epilepsia; 2005; 46 Suppl 9():149-53. PubMed ID: 16302889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.
    Löscher W
    Neurochem Res; 2017 Jul; 42(7):1873-1888. PubMed ID: 28290134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues related to development of antiepileptogenic therapies.
    Pitkänen A; Nehlig A; Brooks-Kayal AR; Dudek FE; Friedman D; Galanopoulou AS; Jensen FE; Kaminski RM; Kapur J; Klitgaard H; Löscher W; Mody I; Schmidt D
    Epilepsia; 2013 Aug; 54 Suppl 4(0 4):35-43. PubMed ID: 23909852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on pharmacotherapy of myoclonic seizures.
    Striano P; Belcastro V
    Expert Opin Pharmacother; 2017 Feb; 18(2):187-193. PubMed ID: 28067060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiepileptic drug therapy in childhood seizures.
    Low PS
    J Singapore Paediatr Soc; 1989; 31(1-2):1-6. PubMed ID: 2504994
    [No Abstract]   [Full Text] [Related]  

  • 19. Epilepsy therapy development: technical and methodologic issues in studies with animal models.
    Galanopoulou AS; Kokaia M; Loeb JA; Nehlig A; Pitkänen A; Rogawski MA; Staley KJ; Whittemore VH; Dudek FE
    Epilepsia; 2013 Aug; 54 Suppl 4(0 4):13-23. PubMed ID: 23909850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of new antiepileptic drugs: challenges, incentives, and recent advances.
    Perucca E; French J; Bialer M
    Lancet Neurol; 2007 Sep; 6(9):793-804. PubMed ID: 17706563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.